Sugi Predict

Sugi Predict / Compounds / SCHEMBL6438245

SCHEMBL6438245

SCHEMBL6438245

C=CC(N)Nc1ccc(NC(N)C=C)c2c1C(=O)c1ccccc1C2=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 5/20 0.41
▸ ADORA2A P29274 3/20 0.41
▸ CSNK1A1 P48729 2/20 0.41
▸ CSNK1D P48730 2/20 0.41
▸ CSNK1G1 Q9HCP0 2/20 0.41
▸ FGR P09769 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ DYRK1A Q13627 1/20 0.41
▸ HIPK2 Q9H2X6 1/20 0.41
▸ MEN1 O00255 7/20 0.41
▸ KMT2A Q03164 7/20 0.41
▸ POLB P06746 4/20 0.41
▸ BLM P54132 3/20 0.41
▸ NSD2 O96028 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ MMP14 P50281 1/20 0.40
▸ TOP2B Q02880 1/20 0.40
▸ MAPT P10636 4/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10622198 0.91 MEN1 (0.54) MAOACSNK1A1CSNK1DCSNK1G1PIM1
SCHEMBL7129850 0.89 MAPT (0.54) MAOAADORA2AMEN1KMT2APOLB
SCHEMBL10767796 0.85 MAOA (0.41) MAOAADORA2ACSNK1A1CSNK1DCSNK1G1
SCHEMBL8610834 0.84 PTPRC (0.43) MEN1KMT2ABLMNSD2TDP1
SCHEMBL8792588 0.82 ECE1 (0.45) MAOAMEN1KMT2ABLMMAPT
SCHEMBL8696627 0.79 MAPT (0.34) MAOAADORA2AMEN1KMT2APOLB
SCHEMBL1802818 0.77 MEN1 (0.42) MAOAADORA2ACSNK1A1CSNK1DCSNK1G1
SCHEMBL4198601 0.77 MAPT (0.46) MAOAADORA2ACSNK1A1CSNK1DCSNK1G1
SCHEMBL11032682 0.75 MEN1 (0.41) MAOAADORA2ACSNK1A1CSNK1DCSNK1G1
SCHEMBL10622320 0.73 CYP19A1 (0.38) MAOAADORA2ACSNK1A1CSNK1DCSNK1G1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256034-A1 Dioxolane analogs for improved inter-cellular delivery ATTARDO GIORGIO 2005-11-17 — — US disclosed
US-6949557-B2 Hydroanthracene based compounds as anticancer agents DABUR RESEARCH FOUNDATION (IN) 2005-09-27 — — US disclosed
US-20040220197-A1 Hydroanthracene based compounds as anticancer agents DABUR RESEARCH FOUNDATION 2004-11-04 — — US disclosed
US-6747039-B2 INHIBITING CELL PROLIFERATION IN MAMMALS ALBANY MOLECULAR RESEARCH, INC. 2004-06-08 — — US disclosed
US-20030225069-A1 Aza-benzothiopyranoindazoles with antitumor activity BARCLAYS BANK PLC, AS THE COLLATERAL AGENT 2003-12-04 — — US disclosed
US-20030212061-A1 Aza-thioxanthenones with antitumor activity ALBANY MOLECULAR RESEARCH, INC. 2003-11-13 — — US disclosed
EP-1324997-A2 DIOXOLANE ANALOGS FOR IMPROVED INTER-CELLULAR DELIVERY Shire Biochem Inc. (CA) 2003-07-09 — — EP disclosed
US-20030013660-A1 Dioxolane analogs for improved inter-cellular delivery SHIRE BIOCHEM INC. (CA) 2003-01-16 — — US disclosed
WO-2002030922-A2 DIOXOLANE ANALOGS FOR IMPROVED INTER-CELLULAR DELIVERY SHIRE BIOCHEM INC. (CA) 2002-04-18 — — WO disclosed
US-6372785-B1 DRUGS FOR ANTIALLERGENS AND ANTIINFLAMMATORY AGENTS KEITH CHAN, PRESIDENT GLOBOASIA, LLC 2002-04-16 — — US disclosed
EP-0253836-A1 PREPARATION OF FLUOROAROMATIC COMPOUNDS IN DISPERSION OF POTASSIUM FLUORIDE. MALLINCKRODT INC (US) 1988-01-27 — — EP disclosed
WO-1987004148-A1 CATALYTIC METHOD FOR PRODUCING FLUOROAROMATIC COMPOUNDS USING BRANCHED ALKYL PYRIDINIUM SALTS MALLINCKRODT, INC. (US) 1987-07-16 — — WO disclosed
WO-1987004151-A1 PREPARATION OF FLUOROAROMATIC COMPOUNDS IN DISPERSION OF POTASSIUM FLUORIDE MALLINCKRODT, INC. (US) 1987-07-16 — — WO disclosed
US-4540788-A CHELATE COMPOUNDS, ANTITUMOR AGENTS AMERICAN CYANAMID COMPANY (US) 1985-09-10 — — US disclosed
US-4540788-A CHELATE COMPOUNDS, ANTITUMOR AGENTS AMERICAN CYANAMID COMPANY (US) 1985-09-10 — — US disclosed
EP-0131787-A2 Novel Schiff bases of (aminoalkyl or substituted aminoalkyl)-amino-9,10-anthracenediones AMERICAN CYANAMID COMPANY (US) 1985-01-23 — — EP disclosed
EP-0131787-A2 Novel Schiff bases of (aminoalkyl or substituted aminoalkyl)-amino-9,10-anthracenediones AMERICAN CYANAMID COMPANY (US) 1985-01-23 — — EP disclosed
EP-0042940-B1 HETEROALKYLENE-BIS-ANTHRAQUINONES AMERICAN CYANAMID COMPANY (US) 1984-06-06 — — EP disclosed
EP-0042940-A1 Heteroalkylene-bis-anthraquinones AMERICAN CYANAMID COMPANY (US) 1982-01-06 — — EP disclosed
US-4278605-A ANTITUMOR AGENTS AMERICAN CYANAMID COMPANY (US) 1981-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225069-A1 Aza-benzothiopyranoindazoles with antitumor activity AZI2, DUT, AADAC MAOA 922/4885ADORA2A 326/4885CSNK1A1 2912/4885
US-20050256034-A1 Dioxolane analogs for improved inter-cellular delivery SLC19A1, SLC29A1, SLC29A2 MAOA 3162/4885ADORA2A 352/4885CSNK1A1 4433/4885
US-20030212061-A1 Aza-thioxanthenones with antitumor activity AZI2, TPMT, MTAP MAOA 1984/4885ADORA2A 166/4885CSNK1A1 1746/4885
US-20030013660-A1 Dioxolane analogs for improved inter-cellular delivery SLC19A1, SLC29A1, SLC29A2 MAOA 3373/4885ADORA2A 441/4885CSNK1A1 4299/4885
US-20040220197-A1 Hydroanthracene based compounds as anticancer agents MCL1, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAOA 3500/4885ADORA2A 2865/4885CSNK1A1 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.